Vanguard Personalized Indexing Management LLC Buys 2,306 Shares of uniQure (NASDAQ:QURE)

Vanguard Personalized Indexing Management LLC lifted its holdings in uniQure (NASDAQ:QURE) by 21.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,301 shares of the biotechnology company’s stock after buying an additional 2,306 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in uniQure were worth $59,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 58.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,664 shares during the last quarter. Pale Fire Capital SE raised its stake in uniQure by 9.2% during the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 5,500 shares in the last quarter. American Century Companies Inc. grew its position in uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 8,642 shares in the last quarter. Clear Harbor Asset Management LLC lifted its holdings in uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 12,500 shares in the last quarter. Finally, Total Clarity Wealth Management Inc. bought a new position in shares of uniQure during the 2nd quarter worth $74,000. 78.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on QURE. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, August 20th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Monday, August 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price target on shares of uniQure in a research note on Friday, September 20th. Finally, The Goldman Sachs Group lifted their price target on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $19.40.

uniQure Stock Down 6.3 %

Shares of uniQure stock opened at $4.62 on Wednesday. The company has a 50 day moving average of $6.36 and a 200 day moving average of $5.63. The company has a market capitalization of $224.30 million, a P/E ratio of -0.79 and a beta of 0.95. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.08. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The firm had revenue of $11.13 million during the quarter, compared to the consensus estimate of $3.47 million. As a group, research analysts forecast that uniQure will post -4.04 EPS for the current fiscal year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.